Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MLGT: 24Mill Flt News release on>China>social>media>merger>pending>
Expecting a news release for US investors at any time.
Great op for MLGT current investors to load up on whatever is left of the tiny 24M float.
NOTE: SnapChat gearing up to make their Spectacles product available for China SnapChat like services?
http://www.businessinsider.com/snapchat-china-office-spectacles-2016-12
MLGT 8-K CHINA RM>24mill Float: 3 Silicon Valley-types>now>at>helm>of>China>SnapChat> clone>*****24mill Float.
MLGT: Hi end Aussie tech investors part owners. Trades on ASX: PAC.
The founder of Shenzhen Zhuomeng Chuangxiang Technology Co., Ltd. is
Ming Lu Zhong.
Most of his relationship links are to Northern Lights Capital.
Relationships Link:
https://relationshipscience.com/ming-lu-zhong-p181333806
Northern Lights Capital is now Pacific Current Group. This company trades on the Aussie Stock Exchange (ASX: PAC).
Link:
http://paccurrent.com/
In December, 2016 Northern Lights (Now absorbed into Pacific Current Group), gave a funding round of $1.2M dollars to Impingo.me..........the SnapChat clone website owned by Shenzhen Zhuomeng Chuangxiang Technology Co., Ltd. I believe Impingo has also received investing rounds from other angel investors that are now alos part owners.
Link:
https://www.techinasia.com/companies/impingome
Shortly thereafter, MLGT merged with Shenzhen Zhuomeng Chuangxiang Technology Co., Ltd.
NOTE: Based on my DD, it appears that the new MLGT owners are backed by and PARTIALLY OWNED by a top tier Aussie high tech angel investing firm with a track record of investing in high end tech growth companies.
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
MLGT is now a hot Asian social media play.
Management are all top tier tech players.
These young guys know what they are doing. The fact that they are now running a company trading in the American stock market is a feather in their cap and an impetus to crank up the volume.
Incredible turn of events for MLGT
From 4/5/17 8-K:
Upon closing, the following person are appointed as our directors and officers effective on March 31, 2017:
Jiyin Li, Age:30, Position:Chairman
Huibin Su. Age:37 Position: Director, Chief Executive Officer and Chief Financial Officer
Zizhong Huang, Age; 28 Position: Chief Operating Officer
Mr. Li, age 30, has served as the Chairman of Shenzhen Chuangxiang Network Technology Co., Ltd, a company that engages in the development of mobile and internet software products. From August 2015 to June 2016, he was also the CEO of Shenzhen Chuangxiang Network Technology Co. Ltd. From October 2012 to June 2015, he served as the Deputy General Manager of Shenzhen E-Life Technology Co., Ltd., a technology company that develops mobile applications and online games. Mr. Li obtained his Bachelor of Art in business management from Huanghe Science &Technology College.
Mr. Li does not have any family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K.
Mr. Su, age 37, has served as the CEO and CFO of Shenzhen Chuangxiang Network Technology Co., Ltd since June 2016. From January 2015 to May 2016, he served as the CFO of Guangzhou Honghuayuan Investments Limited, an investment company that specializes in real estate related investments and fund management. From January 2012 to February 2014, he served as the CFO of Guangzhou Wancai Group Limited, a real estate and tourism development company. From August 2002 to December 2011, he served as the Finance Supervisor of Guangzhou Pharmaceutical Holdings Limited, a pharmaceutical wholesaler and distribution company. Mr. Su obtained his Master Degree in Business Administration from Sun Yat-Sen University.
Mr. Su does not have any family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K.
Mr. Huang, age 28, has served as the COO of Shenzhen Chuangxiang Network Technology Co., Ltd since July 2016. From January 2015 to June 2016, Mr. Li was the co-founder and COO of Dongguan Houhai Asset Management Co., Ltd., an investment company that specializes in equity investments and private fund management. From July 2012 to December 2014, he served as the business manager of Dongguan Rural Commercial Bank. Mr. Huang obtained his Bachelor in business administration from South China Agricultural University.
Mr. Huang does not have any family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K.
NOTE: These talented young guys have the backing and full support, including major financial backing of the Aussie tech investment powerhouse Pacific Current Group (ASX:PAC), via their subsidiary, Northern Lights.
Link:
Pacific Current Group | Global Multi-Boutique Manager
MLGT 8-K CHINA RM>24mill Float: 3 Silicon Valley-types>now>at>helm>of>China>SnapChat> clone>*****24mill Float.
MLGT: Hi end Aussie tech investors part owners. Trades on ASX: PAC.
The founder of Shenzhen Zhuomeng Chuangxiang Technology Co., Ltd. is
Ming Lu Zhong.
Most of his relationship links are to Northern Lights Capital.
Relationships Link:
https://relationshipscience.com/ming-lu-zhong-p181333806
Northern Lights Capital is now Pacific Current Group. This company trades on the Aussie Stock Exchange (ASX: PAC).
Link:
http://paccurrent.com/
In December, 2016 Northern Lights (Now absorbed into Pacific Current Group), gave a funding round of $1.2M dollars to Impingo.me..........the SnapChat clone website owned by Shenzhen Zhuomeng Chuangxiang Technology Co., Ltd. I believe Impingo has also received investing rounds from other angel investors that are now alos part owners.
Link:
https://www.techinasia.com/companies/impingome
Shortly thereafter, MLGT merged with Shenzhen Zhuomeng Chuangxiang Technology Co., Ltd.
NOTE: Based on my DD, it appears that the new MLGT owners are backed by and PARTIALLY OWNED by a top tier Aussie high tech angel investing firm with a track record of investing in high end tech growth companies.
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
MLGT is now a hot Asian social media play.
Management are all top tier tech players.
These young guys know what they are doing. The fact that they are now running a company trading in the American stock market is a feather in their cap and an impetus to crank up the volume.
Incredible turn of events for MLGT
From 4/5/17 8-K:
Upon closing, the following person are appointed as our directors and officers effective on March 31, 2017:
Jiyin Li, Age:30, Position:Chairman
Huibin Su. Age:37 Position: Director, Chief Executive Officer and Chief Financial Officer
Zizhong Huang, Age; 28 Position: Chief Operating Officer
Mr. Li, age 30, has served as the Chairman of Shenzhen Chuangxiang Network Technology Co., Ltd, a company that engages in the development of mobile and internet software products. From August 2015 to June 2016, he was also the CEO of Shenzhen Chuangxiang Network Technology Co. Ltd. From October 2012 to June 2015, he served as the Deputy General Manager of Shenzhen E-Life Technology Co., Ltd., a technology company that develops mobile applications and online games. Mr. Li obtained his Bachelor of Art in business management from Huanghe Science &Technology College.
Mr. Li does not have any family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K.
Mr. Su, age 37, has served as the CEO and CFO of Shenzhen Chuangxiang Network Technology Co., Ltd since June 2016. From January 2015 to May 2016, he served as the CFO of Guangzhou Honghuayuan Investments Limited, an investment company that specializes in real estate related investments and fund management. From January 2012 to February 2014, he served as the CFO of Guangzhou Wancai Group Limited, a real estate and tourism development company. From August 2002 to December 2011, he served as the Finance Supervisor of Guangzhou Pharmaceutical Holdings Limited, a pharmaceutical wholesaler and distribution company. Mr. Su obtained his Master Degree in Business Administration from Sun Yat-Sen University.
Mr. Su does not have any family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K.
Mr. Huang, age 28, has served as the COO of Shenzhen Chuangxiang Network Technology Co., Ltd since July 2016. From January 2015 to June 2016, Mr. Li was the co-founder and COO of Dongguan Houhai Asset Management Co., Ltd., an investment company that specializes in equity investments and private fund management. From July 2012 to December 2014, he served as the business manager of Dongguan Rural Commercial Bank. Mr. Huang obtained his Bachelor in business administration from South China Agricultural University.
Mr. Huang does not have any family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K.
NOTE: These talented young guys have the backing and full support, including major financial backing of the Aussie tech investment powerhouse Pacific Current Group (ASX:PAC), via their subsidiary, Northern Lights.
Link:
Pacific Current Group | Global Multi-Boutique Manager
WARNING: Don't Get Caught Flipping>MMEX>News>ANYTIME>Now.
Hanks>said,"you>don't>go>this>far>without>financing>ALREADY>LINED>UP> ">MMEX>has>ALL Top>Tier>Partners.
This link is readable on a PC to the end and Hanks himself says, "you don't go this far without financing"
http://m.fortstocktonpioneer.com/news/article_c095e8d2-0442-11e7-b6f9-ef65c47e9598.html?mode=jqm
SOON MMEX National Media Coverage>9>HUGE>Catalysts>To>Dimes>
News could Hit Anytime>9>HUGE>Catalysts>Driving>MMEX>To>Dimes>
1-Permits,,,,
2-Valuation,,,
3-Financing(Revelation of Financer),,,
4-Construction,,,,
5-Coverage of the Construction by National Media,,,,
6-National Media attention,,,,,
7-Response/Endorsement from Federal Gov.
8-Ribbon Cutting ceremony,,and Commencing of Operation
9-Revenues
MMEX!
News ANYTIME NOW>9>HUGE>Catalysts>Driving>MMEX>To>Dimes>
1-Permits,,,,
2-Valuation,,,
3-Financing(Revelation of Financer),,,
4-Construction,,,,
5-Coverage of the Construction by National Media,,,,
6-National Media attention,,,,,
7-Response/Endorsement from Federal Gov.
8-Ribbon Cutting ceremony,,and Commencing of Operation
9-Revenues
ALERT: Don't get caught flipping>MMEX>News>ANYTIME>Now.
BINGO! Hanks>says,"you>don't>go>this>far>without>financing>ALREADY>LINED>UP> ">MMEX>has>ALL Top>Tier>Partners.
This link is readable on a PC to the end and Hanks himself says, "you don't go this far without financing"
http://m.fortstocktonpioneer.com/news/article_c095e8d2-0442-11e7-b6f9-ef65c47e9598.html?mode=jqm
Hanks>"you>don't>go>this>far>without>financing>ALREADY>LINED>UP> ">MMEX>has>ALL Top>Tier>Partners.
MMEX Float LOCKED UP-Can Keep Going Now EVEN without News!
This link is readable on a PC to the end and Hanks himself says, "you don't go this far without financing"
http://m.fortstocktonpioneer.com/news/article_c095e8d2-0442-11e7-b6f9-ef65c47e9598.html?mode=jqm
News could Hit Anytime>9>HUGE>Catalysts>Driving>MMEX>To>Dimes>
1-Permits,,,,
2-Valuation,,,
3-Financing(Revelation of Financer),,,
4-Construction,,,,
5-Coverage of the Construction by National Media,,,,
6-National Media attention,,,,,
7-Response/Endorsement from Federal Gov.
8-Ribbon Cutting ceremony,,and Commencing of Operation
9-Revenues
BINGO! Hanks>says,"you>don't>go>this>far>without>financing>ALREADY>LINED>UP> ">MMEX>has>ALL Top>Tier>Partners.
This link is readable on a PC to the end and Hanks himself says, "you don't go this far without financing"
http://m.fortstocktonpioneer.com/news/article_c095e8d2-0442-11e7-b6f9-ef65c47e9598.html?mode=jqm
CONFIRMED ALREADY: MMEX>has>Financing>BASED>ON>VALUATION>RPT>
OCMillionaire Member Level Wednesday, 04/19/17 10:19:13 AM
Re: OCMillionaire post# 44352
Post # of 45659
Financing update 2nd part and Valuation:
******I found the company who gave them part of the financing. I stumbled on it last night so I called MMEX to confirm and he said I am going to have to wait for the news to see if I am right! Oh my gosh this is huge. Going to buy 2-5 million more today :)
The valuation as well I found out, is worth close to what STERVC has posted via company word of mouth. I asked about the .58 cent valuation and his response was:
" Sounds like you have done some extensive research. Looks like Doty Scott isn't the only one who can do math. "
I don't know about you guys but uhm......what does that exactly mean other than its worth around there?!!!!!
Guys, no one gives them THIS MUCH money if its a scam....and oh boy they got a lot for the first round!!!
Also, I will be respectful of the companies wishes and let them tell the story.
MMEX Float Lockup, can go up now>EVEN>without>news.
BINGO! Hanks>says,"you>don't>go>this>far>without>financing>ALREADY>LINED>UP> ">MMEX>has>ALL Top>Tier>Partners.
This link is readable on a PC to the end and Hanks himself says, "you don't go this far without financing"
http://m.fortstocktonpioneer.com/news/article_c095e8d2-0442-11e7-b6f9-ef65c47e9598.html?mode=jqm
BINGO! Hanks>says,"you>don't>go>this>far>without>financing>ALREADY>LINED>UP> ">MMEX>has>ALL Top>Tier>Partners.
This link is readable on a PC to the end and Hanks himself says, "you don't go this far without financing"
http://m.fortstocktonpioneer.com/news/article_c095e8d2-0442-11e7-b6f9-ef65c47e9598.html?mode=jqm
That is the building & New>HQ>of>MLGT>All>Right>
Room 1205, 1A Building, Shenzhen Software Industry Base, Xuefu Rd, Nanshan District, Shenzhen,Guangdong Province, China.
On March 31, 2017, the Company moved its principle office to Room 1205, 1A Building, Shenzhen Software Industry Base, Xuefu Rd, Nanshan District, Shenzhen,Guangdong Province, China. The Company’s telephone and fax numbers also changed, phone: 86-755-26412816, fax: 86-755-26410849.
Yup, MMEX board marks up 250 in 2>weeks>770+!
TVEMF>(ENDV Patented Tech) vs PEMF>(ALL Others)>COMPARISON>
Time-Varying Electromagnetic Field (TVEMF) technology is fundamentally different from other magnetic pulse devices. TVEMF is based on the physics of electricity and magnetism as well as the physiology of cells and tissues.
PEMF devices do not produce square waves, the optimal waveform for a tissue response.
PEMF devices do not produce enough intensity to stimulate a response; most do not even produce 1 Gauss of intensity.
PEMF devices do not produce a rate of induction (slew rate) that is quick enough to penetrate deep within tissues. TVEMF produces pulses that are only 0.0001 seconds wide.
Furthermore, TVEMF features repeating patterns of pulses that are selected based on known motor-neuron stimulation patterns of musculoskeletal tissues.
Why Square Waves?
Sine waves take too long to reach their peak intensity. The lower slew rate means that they are not effective in producing a cellular/tissue response.
Triangle and sawtooth waves also suffer from a lower slew rate, meaning that they are not effective in producing a cellular/tissue response.
Endonovo’s TVEMF device produces a patented square waveform, which was proven the most effective waveform to increase cell growth and the production of over 200 growth factors and cytokines.
Cytotronics™ Platform
Our Cytotronics™ platform uses Time-Varying Electromagnetic Field (TVEMF) technology to expand and enhance the therapeutic properties of stem cells, immune cells and for use in tissue engineering. The goal of our Cytotronics™ platform is to create optimized cell-based therapies with greater therapeutic potential than the un-modulated cells currently being used in regenerative medicine.
The origins of our Cytotronics™ platform dates back to experiments conducted at NASA to expand stem cells ex vivo and to create therapies that could be used to treat astronauts during long term space exploration. The results of those experiments revealed that Time-Varying Electromagnetic Fields (TVEMF) could be used to expand stem cells in the lab and resulted in the increased expression of dozens of genes related to cell growth, tumor suppression, cell adhesion and extracellular matrix production.
A Physics Approach to Biology – Ex Vivo Modulation
We have built upon over 15 years of research and development to create a novel therapeutic paradigm – the systematic enhancement of the biological and therapeutic properties of cells ex vivo. This allows for the creation of a precise, scalable and cost effective approach to maximize the safety and effectiveness of cell-based therapies.
While our competitors are using genetic modification and pharmacological modulation to alter and enhance the biological properties of cells, we are taking A Physics Approach to Biology™ in the use of bioelectronics to create ex vivo modulated cells with enhanced biological and therapeutic properties. Using our Cytotronics™ platform, we are able to create cells that express higher levels of key genes related to stem cell maintenance, cell growth, cell homing and engraftment. Cytotronic™ expansion of peripheral blood stem cells resulted in an over 80-fold expansion of CD34+ cells in as few as 6 days.
Our Cytotronic™ platform was shown to be able to maintain normal human neural progenitor (NHNP) cells in long term culture (180 days), undifferentiated with the ability to be cryogenically preserved then subsequently reintroduced into culture with stem and progenitor markers still intact. NHNP cells that were expanded using our technology were then shown to not be tumorigenic when introduced into nude (athymic) mice for 85 days. Multi-color Fluorescence In Situ Hybridization (mFISH) showed that there was no chromosomal damage to cells subjected to Time-Varying Electromagnetic Fields (TVEMF).
Perivascular Cell Therapy Created Using Cytotronics™
Each year, an estimated 60,000 patients with leukemia and lymphoma need bone marrow transplantation. However, only 25,000 of those patients actually receive a transplant, primarily because the other 35,000 patients are unable to find a fully matched bone marrow donor.
Umbilical cord blood from newborn children is an excellent source of hematopoietic stem cells for stem cell transplants because their immune system is still immature and the stem cells have a lower probability of inducing an adverse immune response in patients. Furthermore, a perfect immunological match between donor and recipient is not necessary, unlike in bone marrow transplants.
However, in most cases a unit of umbilical cord blood contains too few stem cells to treat an adult patient and its use is confined above all to the treatment of children. Numerous patients have better matched cord blood products available (5/6 or 6/6 HLA match), however those products have low cell doses and are not suitable for use in adult patients. This is one of the reasons why less than 3 percent of cord blood collected in the United States is ever used. Low volume cord blood units present the opportunity to expand and/or enhance these unused cord blood units for the widespread use of hematopoietic stem cells in regenerative medicine.
Off-The-Shelf Therapeutic
Our Perivascular Cell Therapy is created using immunologically privileged and immune-modulating stem cells from a portion of the human umbilical cord and co-cultured with adipose-derived stem cells along with cord blood cells to create a perivascular cell mixture that can be used to treat malignant and non-malignant hematological disorders.
Endonovo’s cell therapy is an off-the-shelf therapeutic that can be stored indefinitely in a low temperature freeze without requiring cryopreservation. Our technologies are particularly suited to expand the use and effectiveness of low-volume cord blood units.
More In Vivo-Like Stem Cells
Our off-the-shelf therapeutic is created in a three-dimensional bioreactor using our proprietary Cytotronics™ platform to further expand and enhance the biological properties of the stem cells within the perivascular cell mixture. Our use of a perivascular co-culture in a three-dimensional bioreactor is meant to mimic the way that blood-forming stem cells renew and reside in the body. This simulated stem cell niche allows for the expansion of long-term self-renewing stem cells. Researchers had previously identified endothelial and perivascular cells as the cells that were functionally responsible for the maintenance of blood-forming stem cells (HSCs) in the body. Our technologies provide a method for the expansion of HSCs in an environment that resembles their native stem cell niche..
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=129419388
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=129638466
$15 million dollar cash infusion by secret health care investor. Investors keep buying at .26 average this spending half there salary buying shares on the open market. Multi Dollars double digit dollars and triple digit dollars in the horizon. Anything under .10 is a gift. Soon it will be anything under .26 is a gift.
BINGO! Hanks>says,"you>don't>go>this>far>without>financing>ALREADY>LINED>UP> ">MMEX>has>ALL Top>Tier>Partners.
This link is readable on a PC to the end and Hanks himself says, "you don't go this far without financing"
http://m.fortstocktonpioneer.com/news/article_c095e8d2-0442-11e7-b6f9-ef65c47e9598.html?mode=jqm
News could Hit Anytime>9>HUGE>Catalysts>Driving>MMEX>To>Dimes>
1-Permits,,,,
2-Valuation,,,
3-Financing(Revelation of Financer),,,
4-Construction,,,,
5-Coverage of the Construction by National Media,,,,
6-National Media attention,,,,,
7-Response/Endorsement from Federal Gov.
8-Ribbon Cutting ceremony,,and Commencing of Operation
9-Revenues
MLGT R/M DD: Mega-website WeChat servers>@>same>China>address>
24mill Float:
MLGT R/M DD: China SnapChat clone New HQs>24mill>Float>
Latest 8-K
http://ih.advfn.com/p.php?pid=nmona&article=74399925
New HQs located in the hottest location of China's Silicon valley.
http://www.archdaily.com/780299/shenzhen-software-industry-base-gmp-architekten
NOTE: This may get truly crazy.
------------------------------------------------------------------------
MLGT: Mega-website WeChat servers @ same China address.
1.) The new MLGT HQs in China is located in the same hi-tech building complex as WeChat Shenzhen
2.) Is China social media giant WeChat about to launch a giant IPO via reverse merger with MLGT?
3.) At the very least, are the new MLGT owners linking their website to WeChat servers to piggyback a global website? WeChat has global server access.
Link:
https://www.wechat.com/en/
MLGT R/M DD: Mega-website WeChat servers>@>same>China>address>
24mill Float:
MLGT R/M DD: China SnapChat clone New HQs>24mill>Float>
Latest 8-K
http://ih.advfn.com/p.php?pid=nmona&article=74399925
New HQs located in the hottest location of China's Silicon valley.
http://www.archdaily.com/780299/shenzhen-software-industry-base-gmp-architekten
NOTE: This may get truly crazy.
------------------------------------------------------------------------
MLGT: Mega-website WeChat servers @ same China address.
1.) The new MLGT HQs in China is located in the same hi-tech building complex as WeChat Shenzhen
2.) Is China social media giant WeChat about to launch a giant IPO via reverse merger with MLGT?
3.) At the very least, are the new MLGT owners linking their website to WeChat servers to piggyback a global website? WeChat has global server access.
Link:
https://www.wechat.com/en/
MLGT R/M DD: China SnapChat clone New HQs>24mill>Float>
Latest 8-K
http://ih.advfn.com/p.php?pid=nmona&article=74399925
New HQs located in the hottest location of China's Silicon valley.
http://www.archdaily.com/780299/shenzhen-software-industry-base-gmp-architekten
NOTE: This may get truly crazy.
------------------------------------------------------------------------
MLGT: Mega-website WeChat servers @ same China address.
The new MLGT HQs in China is located in the same hi-tech building complex as WeChat Shenzhen
Is China social media giant WeChat about to launch a giant IPO via reverse merger with MLGT?
At the very least, are the new MLGT owners linking their website to WeChat servers to piggyback a global website? WeChat has global server access.
Link:
https://www.wechat.com/en/
Maple LLC. MOVING 100'$ of Million$>Asset$>into>its>shell>MMEX>
MMEX management team has more than 30 years of experience building and managing multi-million dollar gas processing, pipelines, power plants, refinery and oil and gas operations in Peru and the United States. MMEX purchased the rights to the project from Maple Resources Corporation. As with each of its previous projects, the management team will establish local offices and representatives to keep the surrounding communities informed throughout the construction phase and once the refinery is fully operational.
MLGT: China SnapChat HQs now in SoftWare Park. China>
Great to see.
8-K 4/24/17:
On March 31, 2017, the Company moved its principle office to Room 1205, 1A Building, Shenzhen Software Industry Base, Xuefu Rd, Nanshan District, Shenzhen,Guangdong Province, China. The Company’s telephone and fax numbers also changed, phone: 86-755-26412816, fax: 86-755-26410849
MMEX CEO>commented>“the>refinery>is>progressing> *****smoothly>and>rapidly>*****and the selection of KPE as the project’s EPC contractor is an essential first step to beginning the project. With their strong industry experience, knowledge of the Texas market, scalability and agility, KPE is an ideal partner for MMEX on this project.”
MMEX Resources Partners with KP Engineering to Design, Build Crude Oil Refinery in Permian Basin
AUSTIN, TEXAS, March 29, 2017 (GLOBE NEWSWIRE) -- MMEX Resources Corp. (OTCPK: MMEX), a development stage company focusing on the acquisition, development and financing of oil, gas, refining and infrastructure projects in Texas and South America, and KP Engineering (“KPE”), an energy industry leader in engineering, procurement and construction (EPC) solutions, announced today a partnership for KPE to engineer, design and construct the planned Pecos County refinery announced by MMEX earlier this month.
Jack W. Hanks, President & CEO of MMEX Resources Corp., commented: “Plans for the Pecos County refinery are progressing smoothly and rapidly, and the selection of KPE as the project’s EPC contractor is an essential first step to beginning the project. With their strong industry experience, knowledge of the Texas market, scalability and agility, KPE is an ideal partner for MMEX on this project.”
On March 7, MMEX announced plans to build a crude oil refinery in the Permian Basin near Fort Stockton, Texas, subject to the receipt of required governmental permits and completion of required debt and equity financing. The state-of-the-art refinery project, with plans to export crude oil, fuels and petroleum products to western Mexico and South America, would generate approximately 400 local jobs during peak construction and approximately 100 permanent jobs upon becoming fully operational.
“We are humbled that MMEX Resources has chosen KPE to assist them in constructing a state-of-the-art crude processing and transport facility for the Permian Basin,” said Brandon T. Steele, Chairman and CEO of KP Engineering. “KP Engineering employs some of the finest professionals in the industry and we are excited to be working alongside MMEX Resources Corp. as their EPC firm on this important project and look forward to commencing work immediately.”
MMEX and KPE also announced today that KPE plans to subcontract with Interstate Treating, Inc./RAMA Fabrication, Inc. of Odessa, Texas to engineer and fabricate vessels and process modules for the refinery, allowing for the Pecos County refinery to be constructed using U.S.-sourced materials and equipment.
Hanks concluded: “MMEX Resources is committed to delivering an American-made, state-of-the-art refinery that brings significant economic and job opportunities to the Permian. We’re proud to work alongside KP Engineering, Interstate Treating/RAMA and the Pecos County community to bring the Pecos County refinery to life.”
BINGO! Hanks says,"you>don't>go>this>far>without>financing">MMEX>has>ALL Top>Tier>Partners.
This link is readable on a PC to the end and Hanks himself says, "you don't go this far without financing"
http://m.fortstocktonpioneer.com/news/article_c095e8d2-0442-11e7-b6f9-ef65c47e9598.html?mode=jqm
MMEX On BIG News Watch>(>Could Come Any-Time Now>)
MLGT: China SnapChat HQs now in SoftWare Park. China.
Great to see.
8-K 4/24/17:
On March 31, 2017, the Company moved its principle office to Room 1205, 1A Building, Shenzhen Software Industry Base, Xuefu Rd, Nanshan District, Shenzhen,Guangdong Province, China. The Company’s telephone and fax numbers also changed, phone: 86-755-26412816, fax: 86-755-26410849
MLGT: China SnapChat HQs now in SoftWare Park. China.
Great to see:
8-K 4/24/17:
On March 31, 2017, the Company moved its principle office to Room 1205, 1A Building, Shenzhen Software Industry Base, Xuefu Rd, Nanshan District, Shenzhen,Guangdong Province, China. The Company’s telephone and fax numbers also changed, phone: 86-755-26412816, fax: 86-755-26410849
MLGT: China SnapChat HQs now in SoftWare Park. China.
Great to see:
8-K 4/24/17:
On March 31, 2017, the Company moved its principle office to Room 1205, 1A Building, Shenzhen Software Industry Base, Xuefu Rd, Nanshan District, Shenzhen,Guangdong Province, China. The Company’s telephone and fax numbers also changed, phone: 86-755-26412816, fax: 86-755-26410849
MMEX WAY OVERSOLD on low volume! GEEEEZ
SOON National Media Coverage>9>HUGE>Catalysts>To>Dimes>
News could Hit Anytime>9>HUGE>Catalysts>Driving>MMEX>To>Dimes>
1-Permits,,,,
2-Valuation,,,
3-Financing(Revelation of Financer),,,
4-Construction,,,,
5-Coverage of the Construction by National Media,,,,
6-National Media attention,,,,,
7-Response/Endorsement from Federal Gov.
8-Ribbon Cutting ceremony,,and Commencing of Operation
9-Revenues
MMEX!
TY Jc! Post is re-post thanks to early DD by PROFITABLE I found.
TVEMF>(ENDV Patented Tech) vs PEMF>(ALL Others)>COMPARISON>
Time-Varying Electromagnetic Field (TVEMF) technology is fundamentally different from other magnetic pulse devices. TVEMF is based on the physics of electricity and magnetism as well as the physiology of cells and tissues.
PEMF devices do not produce square waves, the optimal waveform for a tissue response.
PEMF devices do not produce enough intensity to stimulate a response; most do not even produce 1 Gauss of intensity.
PEMF devices do not produce a rate of induction (slew rate) that is quick enough to penetrate deep within tissues. TVEMF produces pulses that are only 0.0001 seconds wide.
Furthermore, TVEMF features repeating patterns of pulses that are selected based on known motor-neuron stimulation patterns of musculoskeletal tissues.
Why Square Waves?
Sine waves take too long to reach their peak intensity. The lower slew rate means that they are not effective in producing a cellular/tissue response.
Triangle and sawtooth waves also suffer from a lower slew rate, meaning that they are not effective in producing a cellular/tissue response.
Endonovo’s TVEMF device produces a patented square waveform, which was proven the most effective waveform to increase cell growth and the production of over 200 growth factors and cytokines.
Cytotronics™ Platform
Our Cytotronics™ platform uses Time-Varying Electromagnetic Field (TVEMF) technology to expand and enhance the therapeutic properties of stem cells, immune cells and for use in tissue engineering. The goal of our Cytotronics™ platform is to create optimized cell-based therapies with greater therapeutic potential than the un-modulated cells currently being used in regenerative medicine.
The origins of our Cytotronics™ platform dates back to experiments conducted at NASA to expand stem cells ex vivo and to create therapies that could be used to treat astronauts during long term space exploration. The results of those experiments revealed that Time-Varying Electromagnetic Fields (TVEMF) could be used to expand stem cells in the lab and resulted in the increased expression of dozens of genes related to cell growth, tumor suppression, cell adhesion and extracellular matrix production.
A Physics Approach to Biology – Ex Vivo Modulation
We have built upon over 15 years of research and development to create a novel therapeutic paradigm – the systematic enhancement of the biological and therapeutic properties of cells ex vivo. This allows for the creation of a precise, scalable and cost effective approach to maximize the safety and effectiveness of cell-based therapies.
While our competitors are using genetic modification and pharmacological modulation to alter and enhance the biological properties of cells, we are taking A Physics Approach to Biology™ in the use of bioelectronics to create ex vivo modulated cells with enhanced biological and therapeutic properties. Using our Cytotronics™ platform, we are able to create cells that express higher levels of key genes related to stem cell maintenance, cell growth, cell homing and engraftment. Cytotronic™ expansion of peripheral blood stem cells resulted in an over 80-fold expansion of CD34+ cells in as few as 6 days.
Our Cytotronic™ platform was shown to be able to maintain normal human neural progenitor (NHNP) cells in long term culture (180 days), undifferentiated with the ability to be cryogenically preserved then subsequently reintroduced into culture with stem and progenitor markers still intact. NHNP cells that were expanded using our technology were then shown to not be tumorigenic when introduced into nude (athymic) mice for 85 days. Multi-color Fluorescence In Situ Hybridization (mFISH) showed that there was no chromosomal damage to cells subjected to Time-Varying Electromagnetic Fields (TVEMF).
Perivascular Cell Therapy Created Using Cytotronics™
Each year, an estimated 60,000 patients with leukemia and lymphoma need bone marrow transplantation. However, only 25,000 of those patients actually receive a transplant, primarily because the other 35,000 patients are unable to find a fully matched bone marrow donor.
Umbilical cord blood from newborn children is an excellent source of hematopoietic stem cells for stem cell transplants because their immune system is still immature and the stem cells have a lower probability of inducing an adverse immune response in patients. Furthermore, a perfect immunological match between donor and recipient is not necessary, unlike in bone marrow transplants.
However, in most cases a unit of umbilical cord blood contains too few stem cells to treat an adult patient and its use is confined above all to the treatment of children. Numerous patients have better matched cord blood products available (5/6 or 6/6 HLA match), however those products have low cell doses and are not suitable for use in adult patients. This is one of the reasons why less than 3 percent of cord blood collected in the United States is ever used. Low volume cord blood units present the opportunity to expand and/or enhance these unused cord blood units for the widespread use of hematopoietic stem cells in regenerative medicine.
Off-The-Shelf Therapeutic
Our Perivascular Cell Therapy is created using immunologically privileged and immune-modulating stem cells from a portion of the human umbilical cord and co-cultured with adipose-derived stem cells along with cord blood cells to create a perivascular cell mixture that can be used to treat malignant and non-malignant hematological disorders.
Endonovo’s cell therapy is an off-the-shelf therapeutic that can be stored indefinitely in a low temperature freeze without requiring cryopreservation. Our technologies are particularly suited to expand the use and effectiveness of low-volume cord blood units.
More In Vivo-Like Stem Cells
Our off-the-shelf therapeutic is created in a three-dimensional bioreactor using our proprietary Cytotronics™ platform to further expand and enhance the biological properties of the stem cells within the perivascular cell mixture. Our use of a perivascular co-culture in a three-dimensional bioreactor is meant to mimic the way that blood-forming stem cells renew and reside in the body. This simulated stem cell niche allows for the expansion of long-term self-renewing stem cells. Researchers had previously identified endothelial and perivascular cells as the cells that were functionally responsible for the maintenance of blood-forming stem cells (HSCs) in the body. Our technologies provide a method for the expansion of HSCs in an environment that resembles their native stem cell niche..
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=129419388
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=129638466
$15 million dollar cash infusion by secret health care investor. Investors keep buying at .26 average this spending half there salary buying shares on the open market. Multi Dollars double digit dollars and triple digit dollars in the horizon. Anything under .10 is a gift. Soon it will be anything under .26 is a gift.
***BEFORE YOU READ ANYTING ELSE ABOUT THIS AMAZING COMPANY PLEASE READ PROPHETABLES STICKY BELOW***
1. Pre-Clinical Studies To Be Completed 2nd Q 2017
2. Application for IND Orphan Drug Status for its Cytotronics Product
3. Over 20 Patent Applications OWNED by the CEO and the Company
4. 10 Form 4s filed since Dec 2016 for Insider purchases of stock
5. A "Strategic Healthcare" Institutional Investor has Ponied up $15 mil to buy back Converts
6. Company paying off the rest of its debt with $2.2 million
7. Uplistment to a "National" exchange being considered
8. Has won their injunction against Kodiak Capital and other Financiers for diluting the stock
Endonovo Evaluating Therapeutic Potential of Non-Invasive Electroceutical Device Following Myocardial Infarction
Electromagnetic pulses are responsible for many of the activities in our bodies. They are an integral part of what keeps our hearts beating and brains functioning.
The bioelectronics device is a portable Time-Varying Electromagnetic Field (TVEMF) system. The unit uses a sophisticated miniaturized circuit board that delivers the specifically designed and patented electromagnetic field to a designated area of the body through the use of antennas (coils).
TVEMF>(ENDV Patented Tech) vs PEMF>(ALL Others)
Time-Varying Electromagnetic Field (TVEMF) technology is fundamentally different from other magnetic pulse devices. TVEMF is based on the physics of electricity and magnetism as well as the physiology of cells and tissues.
PEMF devices do not produce square waves, the optimal waveform for a tissue response.
PEMF devices do not produce enough intensity to stimulate a response; most do not even produce 1 Gauss of intensity.
PEMF devices do not produce a rate of induction (slew rate) that is quick enough to penetrate deep within tissues. TVEMF produces pulses that are only 0.0001 seconds wide.
Furthermore, TVEMF features repeating patterns of pulses that are selected based on known motor-neuron stimulation patterns of musculoskeletal tissues.
Why Square Waves?
Sine waves take too long to reach their peak intensity. The lower slew rate means that they are not effective in producing a cellular/tissue response.
Triangle and sawtooth waves also suffer from a lower slew rate, meaning that they are not effective in producing a cellular/tissue response.
Endonovo’s TVEMF device produces a patented square waveform, which was proven the most effective waveform to increase cell growth and the production of over 200 growth factors and cytokines.
Cytotronics™ Platform
Our Cytotronics™ platform uses Time-Varying Electromagnetic Field (TVEMF) technology to expand and enhance the therapeutic properties of stem cells, immune cells and for use in tissue engineering. The goal of our Cytotronics™ platform is to create optimized cell-based therapies with greater therapeutic potential than the un-modulated cells currently being used in regenerative medicine.
The origins of our Cytotronics™ platform dates back to experiments conducted at NASA to expand stem cells ex vivo and to create therapies that could be used to treat astronauts during long term space exploration. The results of those experiments revealed that Time-Varying Electromagnetic Fields (TVEMF) could be used to expand stem cells in the lab and resulted in the increased expression of dozens of genes related to cell growth, tumor suppression, cell adhesion and extracellular matrix production.
A Physics Approach to Biology – Ex Vivo Modulation
We have built upon over 15 years of research and development to create a novel therapeutic paradigm – the systematic enhancement of the biological and therapeutic properties of cells ex vivo. This allows for the creation of a precise, scalable and cost effective approach to maximize the safety and effectiveness of cell-based therapies.
While our competitors are using genetic modification and pharmacological modulation to alter and enhance the biological properties of cells, we are taking A Physics Approach to Biology™ in the use of bioelectronics to create ex vivo modulated cells with enhanced biological and therapeutic properties. Using our Cytotronics™ platform, we are able to create cells that express higher levels of key genes related to stem cell maintenance, cell growth, cell homing and engraftment. Cytotronic™ expansion of peripheral blood stem cells resulted in an over 80-fold expansion of CD34+ cells in as few as 6 days.
Our Cytotronic™ platform was shown to be able to maintain normal human neural progenitor (NHNP) cells in long term culture (180 days), undifferentiated with the ability to be cryogenically preserved then subsequently reintroduced into culture with stem and progenitor markers still intact. NHNP cells that were expanded using our technology were then shown to not be tumorigenic when introduced into nude (athymic) mice for 85 days. Multi-color Fluorescence In Situ Hybridization (mFISH) showed that there was no chromosomal damage to cells subjected to Time-Varying Electromagnetic Fields (TVEMF).
Perivascular Cell Therapy Created Using Cytotronics™
Each year, an estimated 60,000 patients with leukemia and lymphoma need bone marrow transplantation. However, only 25,000 of those patients actually receive a transplant, primarily because the other 35,000 patients are unable to find a fully matched bone marrow donor.
Umbilical cord blood from newborn children is an excellent source of hematopoietic stem cells for stem cell transplants because their immune system is still immature and the stem cells have a lower probability of inducing an adverse immune response in patients. Furthermore, a perfect immunological match between donor and recipient is not necessary, unlike in bone marrow transplants.
However, in most cases a unit of umbilical cord blood contains too few stem cells to treat an adult patient and its use is confined above all to the treatment of children. Numerous patients have better matched cord blood products available (5/6 or 6/6 HLA match), however those products have low cell doses and are not suitable for use in adult patients. This is one of the reasons why less than 3 percent of cord blood collected in the United States is ever used. Low volume cord blood units present the opportunity to expand and/or enhance these unused cord blood units for the widespread use of hematopoietic stem cells in regenerative medicine.
Off-The-Shelf Therapeutic
Our Perivascular Cell Therapy is created using immunologically privileged and immune-modulating stem cells from a portion of the human umbilical cord and co-cultured with adipose-derived stem cells along with cord blood cells to create a perivascular cell mixture that can be used to treat malignant and non-malignant hematological disorders.
Endonovo’s cell therapy is an off-the-shelf therapeutic that can be stored indefinitely in a low temperature freeze without requiring cryopreservation. Our technologies are particularly suited to expand the use and effectiveness of low-volume cord blood units.
More In Vivo-Like Stem Cells
Our off-the-shelf therapeutic is created in a three-dimensional bioreactor using our proprietary Cytotronics™ platform to further expand and enhance the biological properties of the stem cells within the perivascular cell mixture. Our use of a perivascular co-culture in a three-dimensional bioreactor is meant to mimic the way that blood-forming stem cells renew and reside in the body. This simulated stem cell niche allows for the expansion of long-term self-renewing stem cells. Researchers had previously identified endothelial and perivascular cells as the cells that were functionally responsible for the maintenance of blood-forming stem cells (HSCs) in the body. Our technologies provide a method for the expansion of HSCs in an environment that resembles their native stem cell niche..
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=129419388
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=129638466
$15 million dollar cash infusion by secret health care investor. Investors keep buying at .26 average this spending half there salary buying shares on the open market. Multi Dollars double digit dollars and triple digit dollars in the horizon. Anything under .10 is a gift. Soon it will be anything under .26 is a gift.
$ENDV
Endonovo Evaluating Therapeutic Potential of Non-Invasive Electroceutical Device Following Myocardial Infarction
Pre-Clinical Study to Determine Effectiveness of the Company's Immunotronics(TM) Platform in the Prevention of Heart Failure Following Myocardial Infarction
LOS ANGELES, CA -- (Marketwired) -- 12/19/16 -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a developer of non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions, today announced it is commencing a pre-clinical study at a contract research organization to assess the therapeutic potential of its Immunotronics™ platform in the prevention of heart failure following myocardial infarction (MI). The pre-clinical study will evaluate the effect of the Company's non-invasive electroceutical technology on cardiac function, post-MI remodeling, and infarct size, as well as angiogenesis (the development of new blood vessels). The study, estimated to be complete at the end of the first quarter of 2017, represents the first of several planned studies designed to evaluate the Company's proprietary non-invasive electroceuticals in the treatment of vascular diseases and ischemia/reperfusion injury.
"We are leveraging the experience and proprietary knowledge of our scientific team, which has undertaken over 25 years of research and development in the field of bioelectromagnetic therapeutics in angiogenesis, neuroinflammation and ischemia to develop non-invasive treatments for substantially unmet clinical needs," commented Endonovo Chairman and CEO, Alan Collier.
"A positive result in this study would represent a significant milestone for Endonovo and the field of bioelectronic medicine. We are moving to establish Endonovo as the leader in electroceuticals-based regenerative medicine. Our competitors in the bioelectronic medicine space are primarily developing implantable devices targeting the inflammatory response, and our competitors in regenerative medicine are developing cell therapies, biologics and gene therapies to treat many of these diseases, which are more expensive to develop and present significantly more safety concerns for potential patients.
"Our technology presents a lucrative opportunity to develop a non-invasive platform device that can be used to treat cardiovascular, cerebrovascular and peripheral artery disease as well as ischemia/reperfusion injuries," concluded Mr. Collier.
The Company had previously announced receiving a term sheet for $5 million in preferred financing from a strategic healthcare investor to develop a pipeline in vascular diseases, peripheral artery disease and ischemia/reperfusion injury. The $5 million proposed financing is part of a larger $15 million round of financing to uplist the Company's common stock onto a national stock exchange in the first half of 2017.
About Heart Disease
Coronary artery disease (CAD) is the leading cause of death in the United States, with approximately 500,000 to 700,000 deaths related to CAD occurring each year.
In the United States, approximately 1.1 million cases of myocardial infarction (MI) occur annually, according to the American Heart Associations' Heart Disease and Stroke Statistics -- 2016 Update. MI is a condition where myocardial ischemia, a diminished blood supply to the heart, exceeds a critical threshold and overwhelms myocardial cellular repair mechanisms designed to maintain normal operating function and homeostasis. Ischemia at this critical threshold level for an extended period results in irreversible myocardial cell damage or death, and can result in heart failure.
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a leading developer of bioelectronic-applications in cell therapies and non-invasive electroceuticals. Endonovo's Immunotronics™ platform is dedicated to treating patients with life-threatening inflammatory conditions in vital organs using proprietary non-invasive electroceutical devices. The Company's non-invasive platform is based on magnetically-induced electrical field pathways that target the disruption of inflammation and cell death.
The Company's Cytotronics™ platform harnesses the bulk electrical properties of cells and tissues, namely magnetically-induced electrical field pathways to expand and enhance the therapeutic potential of cell therapies and produce next-generation biologics.
http://ir.endonovo.com/press-releases/detail/218/endonovo-evaluating-therapeutic-potential-of-non-invasive
http://endonovo.com/bioelectronics/
---------------------------------------------------------------------------------------------------------
Cytotronics™ Platform
Our Cytotronics™ platform uses Time-Varying Electromagnetic Field (TVEMF) technology to expand and enhance the therapeutic properties of stem cells, immune cells and for use in tissue engineering. The goal of our Cytotronics™ platform is to create optimized cell-based therapies with greater therapeutic potential than the un-modulated cells currently being used in regenerative medicine.
The origins of our Cytotronics™ platform dates back to experiments conducted at NASA to expand stem cells ex vivo and to create therapies that could be used to treat astronauts during long term space exploration. The results of those experiments revealed that Time-Varying Electromagnetic Fields (TVEMF) could be used to expand stem cells in the lab and resulted in the increased expression of dozens of genes related to cell growth, tumor suppression, cell adhesion and extracellular matrix production.
A Physics Approach to Biology – Ex Vivo Modulation
We have built upon over 15 years of research and development to create a novel therapeutic paradigm – the systematic enhancement of the biological and therapeutic properties of cells ex vivo. This allows for the creation of a precise, scalable and cost effective approach to maximize the safety and effectiveness of cell-based therapies.
While our competitors are using genetic modification and pharmacological modulation to alter and enhance the biological properties of cells, we are taking A Physics Approach to Biology™ in the use of bioelectronics to create ex vivo modulated cells with enhanced biological and therapeutic properties. Using our Cytotronics™ platform, we are able to create cells that express higher levels of key genes related to stem cell maintenance, cell growth, cell homing and engraftment. Cytotronic™ expansion of peripheral blood stem cells resulted in an over 80-fold expansion of CD34+ cells in as few as 6 days.
Our Cytotronic™ platform was shown to be able to maintain normal human neural progenitor (NHNP) cells in long term culture (180 days), undifferentiated with the ability to be cryogenically preserved then subsequently reintroduced into culture with stem and progenitor markers still intact. NHNP cells that were expanded using our technology were then shown to not be tumorigenic when introduced into nude (athymic) mice for 85 days. Multi-color Fluorescence In Situ Hybridization (mFISH) showed that there was no chromosomal damage to cells subjected to Time-Varying Electromagnetic Fields (TVEMF).
ex vivo modulation
Perivascular Cell Therapy Created Using Cytotronics™
Each year, an estimated 60,000 patients with leukemia and lymphoma need bone marrow transplantation. However, only 25,000 of those patients actually receive a transplant, primarily because the other 35,000 patients are unable to find a fully matched bone marrow donor.
Umbilical cord blood from newborn children is an excellent source of hematopoietic stem cells for stem cell transplants because their immune system is still immature and the stem cells have a lower probability of inducing an adverse immune response in patients. Furthermore, a perfect immunological match between donor and recipient is not necessary, unlike in bone marrow transplants.
However, in most cases a unit of umbilical cord blood contains too few stem cells to treat an adult patient and its use is confined above all to the treatment of children. Numerous patients have better matched cord blood products available (5/6 or 6/6 HLA match), however those products have low cell doses and are not suitable for use in adult patients. This is one of the reasons why less than 3 percent of cord blood collected in the United States is ever used. Low volume cord blood units present the opportunity to expand and/or enhance these unused cord blood units for the widespread use of hematopoietic stem cells in regenerative medicine.
Off-The-Shelf Therapeutic
Our Perivascular Cell Therapy is created using immunologically privileged and immune-modulating stem cells from a portion of the human umbilical cord and co-cultured with adipose-derived stem cells along with cord blood cells to create a perivascular cell mixture that can be used to treat malignant and non-malignant hematological disorders.
Endonovo’s cell therapy is an off-the-shelf therapeutic that can be stored indefinitely in a low temperature freeze without requiring cryopreservation. Our technologies are particularly suited to expand the use and effectiveness of low-volume cord blood units.
More In Vivo-Like Stem Cells
Our off-the-shelf therapeutic is created in a three-dimensional bioreactor using our proprietary Cytotronics™ platform to further expand and enhance the biological properties of the stem cells within the perivascular cell mixture. Our use of a perivascular co-culture in a three-dimensional bioreactor is meant to mimic the way that blood-forming stem cells renew and reside in the body. This simulated stem cell niche allows for the expansion of long-term self-renewing stem cells. Researchers had previously identified endothelial and perivascular cells as the cells that were functionally responsible for the maintenance of blood-forming stem cells (HSCs) in the body. Our technologies provide a method for the expansion of HSCs in an environment that resembles their native stem cell niche.
Millionaires will be made on ENDV
$ENDV
MMEX ALREADY has 1st Tranch>of>Financing>BASED>ON>VALUATION>RPT>
OCMillionaire Member Level Wednesday, 04/19/17 10:19:13 AM
Re: OCMillionaire post# 44352
Post # of 45659
Financing update 2nd part and Valuation:
******I found the company who gave them part of the financing. I stumbled on it last night so I called MMEX to confirm and he said I am going to have to wait for the news to see if I am right! Oh my gosh this is huge. Going to buy 2-5 million more today :)
The valuation as well I found out, is worth close to what STERVC has posted via company word of mouth. I asked about the .58 cent valuation and his response was:
" Sounds like you have done some extensive research. Looks like Doty Scott isn't the only one who can do math. "
I don't know about you guys but uhm......what does that exactly mean other than its worth around there?!!!!!
Guys, no one gives them THIS MUCH money if its a scam....and oh boy they got a lot for the first round!!!
Also, I will be respectful of the companies wishes and let them tell the story.
MMEX is ONE PR Away From .05-.10>(NEWS>ANYTIME>ANYDAY>)